In This Section

AACR Special Conference: Targeting RAS

March 5-8, 2023
Philadelphia Marriott Downtown
Philadelphia, Pennsylvania

Register for On-Demand Access: Available through May 17, 2023

Conference Cochairs

Mariano Barbacid, Spanish National Cancer Center (CNIO), Madrid, Spain
Dafna Bar-Sagi, New York University Langone Medical Center, New York, New York
Frank McCormick, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, California
Deborah K. Morrison, National Cancer Institute, Frederick, Maryland

Despite 40+ years of research on RAS genes – which drive growth in approximately one-third of all cancers – the cancer and biomedical research field is just starting to peel away the label of RAS as an “undruggable target.”  The prognosis for many patients with RAS mutations (KRAS, NRAS, HRAS) continues to be poor, but incremental recent progress shows some promise in decreasing the clinical burden across several disease sites. Given the prominent role of RAS in so many human cancers, a comprehensive and in-depth forum for all constituents interested in RAS research is necessary to expand our knowledge of both the basic research pushing the field forward and the exciting potential for clinical application that translational science is advancing. This AACR Special Conference will cover a range of the topics including drug targeting, immunotherapy, metabolism, RASopathies, RAS structure and function, signaling networks, and several talks on RAS disease sites that provide opportunities for cross-cutting education.


Mirati Therapeutics

Reaction Biology Corporation

Verastem Oncology

Continuing Medical Education Activity AMA PRA Category 1 CreditsTM available